Safety and Effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial

Juan J Jiménez1*, José L Iribarren1, Maitane Brouard1, Domingo Hernández2, Salomé Palmero1, Alejandro Jiménez3, Leonardo Lorente1, Patricia Machado4, Juan M Borreguero5, José M Rayaz4, Beatriz Martín5, Rosalía Pérez1, Rafael Martínez5 and María L Mora1

Abstract

Background: In cardiopulmonary bypass (CPB) patients, fibrinolysis may enhance postoperative inflammatory response. We aimed to determine whether an additional postoperative dose of antifibrinolytic tranexamic acid (TA) reduced CPB-mediated inflammatory response (IR).

Methods: We performed a randomized, double-blind, dose-dependent, parallel-groups study of elective CPB patients receiving TA. Patients were randomly assigned to either the single-dose group (40 mg/Kg TA before CPB and placebo after CPB) or the double-dose group (40 mg/Kg TA before and after CPB).

Results: 160 patients were included, 80 in each group. The incident rate of IR was significantly lower in the double-dose-group TA2 (7.5% vs. 18.8% in the single-dose group TA1; \(P = 0.030\)). After adjusting for hypertension, total protamine dose and temperature after CPB, TA2 showed a lower risk of IR compared with TA1 [OR: 0.29 (95% CI: 0.10-0.83), \(P = 0.013\)]. Relative risk for IR was 2.5 for TA1 (95% CI: 1.02 to 6.12). The double-dose group had significantly lower chest tube bleeding at 24 hours [671 (95% CI 549-793 vs. 826 (95% CI 704-949) mL; \(P = 0.01\)] corrected-P significant] and lower D-dimer levels at 24 hours [489 (95% CI 437-540) vs. 621(95% CI: 563-679) ng/mL; \(P = 0.01\) corrected-P significant]. TA2 required lower levels of norepinephrine at 24 h [0.06 (95% CI: 0.03-0.09) vs. 0.20(95 CI: 0.05-0.35) after adjusting for dobutamine \(F = 6.6; P = 0.014\) corrected-P significant].

We found a significant direct relationship between IL-6 and temperature \((\rho = 0.26; P < 0.01)\), D-dimer \((\rho = 0.24; P < 0.01)\), norepinephrine \((\rho = 0.33; P < 0.01)\), troponin I \((\rho = 0.37; P < 0.01)\), Creatine-Kinase \((\rho = 0.37; P < 0.01)\), Creatine Kinase-MB \((\rho = 0.33; P < 0.01)\) and lactic acid \((\rho = 0.46; P < 0.01)\) at ICU arrival. Two patients (1.3%) had seizure, 3 patients (1.9%) had stroke, 14 (8.8%) had acute kidney failure, 7 (4.4%) needed dialysis, 3 (1.9%) suffered myocardial infarction and 9 (5.6%) patients died. We found no significant differences between groups regarding these events.

Conclusions: Prolonged inhibition of fibrinolysis, using an additional postoperative dose of tranexamic acid reduces inflammatory response and postoperative bleeding (but not transfusion requirements) in CPB patients. A question which remains unanswered is whether the dose used was ideal in terms of safety, but not in terms of effectiveness.

Current Controlled Trials number: ISRCTN: ISRCTN84413719

Keywords: Cardiac surgery, Cardiopulmonary bypass, Fibrinolysis, Tranexamic acid, Inflammatory response, Bleeding
Background
Excessive bleeding and inflammatory response (IR) after cardiopulmonary bypass (CPB) are common complications of cardiac surgery [1]. Although tranexamic acid (TA), a lysine analog competitive inhibitor of plasmin and plasminogen [2], is effective in reducing bleeding after cardiac surgery, its anti-inflammatory effect in fibrinolysis blockade has been less studied.

In vitro studies suggest that the exposure of D-dimer fragments to monocytes initiates the synthesis and release of IL-6 [3]. Excessive plasmin activity and/or D-dimer formation may play an important role in proinflammatory cytokine and cellular response activation during CPB [4]. In patients undergoing elective CPB, prophylactic blockade of fibrinolysis decreases molecular expression of IR [5]. This IR may contribute to postoperative complications, including myocardial dysfunction, respiratory failure, renal and neurologic dysfunction, bleeding disorders, altered liver function, and ultimately, multiple organ failure (MOF) [4]. In a previous study using TA before and after CPB we observed reduced bleeding and IR [6]. These results were encouraging but left unanswered the question of whether the postoperative dose, coinciding with greatest fibrinolytic activation, was determinant in decreasing postoperative IR and bleeding. Nevertheless newer data indicate that, in a dose-dependent fashion, TA is associated with an increase of adverse events, particularly the observation of seizures [7]. The incidence of this adverse effect varies from 2.7% to 4.6% in any major surgical procedure, independently of dosing schedule [8-10]. For this reason, we also focused on the safety profile of TA dosing schedule as a part of the study.

Methods
The study was approved by our university hospital ethics committee and conducted according to the Helsinki Declaration. We report this trial in accordance with the CONSORT statement revised recommendations [11].

From December 2005 to January 2007, we performed a randomized, double-blind, dose-dependent parallel-groups study with 160 consecutive adult patients undergoing elective CPB, in a 24-bed intensive care unit (ICU) at a university hospital.

Exclusion criteria included: no informed consent, age <18 years, emergencies, off-pump cardiac surgery, chronic coagulopathy (prothrombin time [PT] <50% or international normalized ratio (INR) >2 and platelets <50,000/mm³ or aggregation dysfunction), renal failure (creatinine >2 mg/dL), gross hematuria, TA hypersensibility, chronic hepatopathy (Child-B or higher), immunosuppression, endocarditis and post-operative sepsis within 24 h.

Before CPB, all participants had normal bleeding time, platelet collagen/epinephrine and collagen/ADP closure time, PT, activated partial thromboplastin time, and thrombin time. No patients received anti-inflammatory or immunosuppressive agents during 5 days before and 24 h post-CPB.

After obtaining written informed consent, the surgeon requested treatment group assignment immediately before CPB.

TA dosing schedule
Dosing schedules for prophylactic TA vary greatly [12,13]. In our center, the TA dosing schedule is an initial bolus (25 mg/Kg) before CPB and another (25 mg/Kg) after completion of CPB. Our first study dealing with TA versus placebo was carried out using this schedule, which has demonstrated its effectiveness in relation to bleeding and IR [6]. Given the half-life of TA (80 min), the initial dose inhibits intra-operative fibrinolysis and bleeding. A loading dose higher than 30 mg/Kg assures a 98-100% reduction of tissue activator activity [14]. Thus the dose schedule used in our study ensured complete inhibition of fibrinolysis during and early postoperative period after CPB, although no pharmacokinetic information was available. With the second dose we wished to investigate the possible benefit of postoperative inhibition of fibrinolysis on IR.

The patients were randomly assigned, by an independent pharmacist according to a computer generated randomization list allocated in the Pharmacology Department, to receive disguised coded infusions of either TA 40 mg/Kg before CPB and placebo after CPB (TA1) or TA 40 mg/Kg before and after CPB (TA2) after heparin reversal. The code was revealed once recruitment, data collection, and laboratory analyses were completed.

Anesthetic procedures
Anesthetic procedures were standardized and consisted of an opioid-based anesthetic supplemented with volatile anesthetic and muscle relaxants. All interventions were performed by the same surgical team with wide experience in these surgical interventions. All patients were preoperatively monitored with a pulmonary artery continuous thermodilution catheter (Edwards Lifesciences LLC, Irvine, CA, USA). Neither heparin-coated circuits nor leukocyte filters were used. The extracorporeal circuit consisted of a hardshell membrane oxygenator (Optima XP; Cobe, Denver, CO, USA, or Quantum Lifestream International, Inc., Woodlands, TX, USA), a Tygon™ (Dideco s.r.l., Mirandola, Italy) extracorporeal circuit, and a Medtronic™ Bionpump (Medtronic, Inc., Minneapolis, MN, USA) centrifugal pump. Below hypothermic temperatures of 28°C to 30°C, the pump flow was adjusted to maintain a mean arterial pressure of greater than 60 mm Hg and a flow index of 2.2 L/minute per square meter. Myocardial protection was achieved using antegrade, cold, St. Thomas 4:1 sanguineous cardioplegia. The circuit was primed with
30 mg of heparin followed by an initial dose of 3 mg/kg and further doses when necessary to achieve and maintain an activated clotting time of 480 seconds. To reverse the effect of heparin, protamine was used based on blood heparin levels measured by Hepcon® (Medtronic, Inc.). A blood salvage device (Cobe BRAT2™, Cobe Cardiovascular Inc.TX, USA) was used in all patients. The transfusion trigger was a hemoglobin threshold of less than 8 g/dL, PT of less than 50%, and platelets of less than 50,000/mm3. Fluid management was carried out to achieve 8 to 12 mm Hg of central venous pressure or 12 to 15 mm Hg of pulmonary artery occlusion pressure at zero positive end-expiratory pressure by infusions of crystalloids and colloids. Following our routine practice, we used Ringer Lactate or Saline 0.9% in the intra-operative period. After patient admission to ICU, crystalloids were mainly used and when colloids were infused we most commonly used HES 130/0.4 (Voluven ®), not exceeding 1000 ml in 24 hours.

Catecholamine support, when necessary, was used as follows: Norepinephrine was titrated to achieve a mean arterial pressure of greater or equal to 70 mm Hg, and dobutamine was titrated to achieve a cardiac index of greater or equal to 2.5 L/minute per square meter. Amines were tapered off in steps of 0.02 and 1 μg/kg per minute, respectively.

Concurrent validation
We validated the clinical criteria of IR and found significant differences in evolutionary levels of IL-6 in patients who developed IR versus those without.

Data collection
Demographic variables, comorbidity, perioperative clinical data, and postoperative IR, mechanical ventilation time, ICU and hospital stay, and mortality, were recorded. Core body temperature, laboratory data (hematology, inflammation, coagulation, and fibrinolysis), and hemodynamic parameters were recorded before intervention (baseline), on ICU admission after surgery (0 h), and at 4 h and 24 h post-CPB, once hemodynamic stability was confirmed. IR was clinically defined as core body temperature >38°C (100.4°F), systemic vascular resistance index <1,600 dyn sec/cm5 per m2, and cardiac index >3.5 L/minute per m2 at 4 h, as we reported in a previous study [6]. We also recorded blood loss (chest-tube drainage and hemoderivatives) at the above time points and on chest tubes removal. In cases of reintervention due to bleeding, the post-hoc classification of bleeding into "surgical" and "non-surgical" was applied to distinguish between bleeding due to mechanical-surgical causes (where pharmacological measures are not effective) and coagulopathy (which TA was expected to reduce). Surgical risk was calculated by Euroscore and Parsonnet score.

Cerebrovascular events included seizure and stroke. Acute kidney injury was assessed applying RIFLE [15] criteria (>100% creatinine increase, using preoperative and highest creatinine concentration during the first week after surgery); renal failure was defined as dysfunction requiring dialysis. Myocardial infarction was considered as either new Q waves or new, persistent ST-segment or T-wave changes. Indication for re-operation was determined by clinical judgment and blood loss as >200 ml/h in three consecutive hours. Mortality was defined as death within 30 days of CPB, recorded in medical history or telephone contact with the surgeon responsible or family. These adverse effects were included as a composite variable.

Cytokine levels
IL-6 (normal range: <5.9 pg/mL; intra-assay variation: 4.5%) was measured by automatic immunoenzyme assay (IMMULITE ONETM; Diagnostic Products Corporation).

Coagulation and fibrinolysis determination
D-dimer (normal range: <300 ng/mL; intra-assay variation: 3%) was measured by immunoturbidimetric test (D-dimer PLUS; Dade Behring).

Statistical analysis
Sample size
In relation to the power of the study, prior experimental information available is as follows: the proportion of IR in patients receiving 30 mg/kg in two doses was 16.6% [6]; however, we had no prior information on the expected incidence rate of IR with 80 mg/kg. In the present study, we hypothesized that the double dose of TA would reduce the inflammatory response. For expected incidences of 16.6% in the TA1 group (40-0 mg/Kg) and 3% in the TA2 group, with 80% power and 5% type one error (one-tailed), 58 patients per group were needed. Assuming 28% dropout, 80 patients were required in each treatment group.

For the concurrent validation of the clinical criteria of IR, we used mixed ANOVA with repeated measures of evolutionary levels of IL-6 (baseline, at ICU arrival, and at 4 h postoperatively), after log-transformation. The intergroup variable was IR (yes or no). After applying the Bonferroni correction, differences with a p value of <0.018 were considered significant.

Comparisons between groups (TA1 versus TA2) were performed per protocol analyses, using Pearson’s χ² test or Fischer’s exact test for categorical variables, and Student’s t-test or Mann-Whitney’s U test for continuous variables. Assumption of normality of the TA groups was tested with the Kolmogorov-Smirnov test, and homoscedasticity was tested with the Levene test. When any adjustment or multiple comparisons were necessary on applying analysis of covariance or mixed ANOVA, the
variables were previously log-transformed to ensure normal distribution and homoscedasticity.

All preoperative variables showing a $P$ value $< 0.15$ in the bivariate analysis (hypertension, post-CPB temperature, total protamine dose) were entered in a multivariate binary logistic regression analysis, for categorical primary end-point outcome (IR).

Mixed ANOVA was used to compare means between groups in clinical signs (bleeding) and laboratory parameters (D-dimer, creatine kinase and troponin I) at baseline, 4 h and 24 h after surgery. For bleeding and D-dimer, correction for multiple variables was not carried out in the omnibus test because of the a priori known unidirectional nature of the effects of TA on these parameters. However, any isolated values in repeated measures were considered significant when $P < 0.018$, after applying Bonferroni correction. In the case of 24 h bleeding, this was adjusted for surgery-related bleeding.

To test the effect of TA on 24 h postoperative norepinephrine requirements, the statistical analysis included adjustment for the use of dobutamine. After applying Bonferroni correction, differences with a $P$ value of $< 0.018$ were considered significant.

Bivariate associations between IL-6 and D-dimer, chest-tube bleeding, norepinephrine dose, temperature, troponin I (TnI), creatine kinase (CK), MB isoenzyme creatine kinase (CK-MB) and blood pressure were assessed using Spearman’s rho coefficient.

Qualitative variables were expressed as frequencies and percentages and quantitative variables as mean and 95% confidence interval (CI), or median and interquartile range. $P$ values of $< 0.05$ were considered significant. SPSS 15.0.1 (SPSS Inc. Chicago, IL. USA) and Statistica 8.0 (StatSoft, Tulsa, OK) were used.

Results

From December 2005 to January 2007, we recruited 209 consecutive CPB patients; 49 were excluded (20 off-pump, 4 coagulation disorders, 11 emergencies, 6 endocarditis, 4 hemodialysis, and 4 immunosuppressed). Thus we studied 160 patients, 80 receiving single-dose TA before CPB and 80 receiving TA before and after CPB. Figure 1 shows a flow chart of patients enrolled.

Demographic variables, comorbidity, medical treatment, preoperative biochemical data, and surgical procedures were similar in the two groups, except for post-CPB temperature and total protamine dose (Table 1).

Patients developing IR showed significantly higher levels of IL-6 at 4 h postoperatively than those without IR, $[F(2, 274) = 5.08; P = 0.013]$, (Figure 2).

The incident rate of IR was significantly lower in TA2 (7.5%) than in TA1 (18.8%) ($P = 0.030$). TA2 showed OR 0.29 (95%CI: 0.10-0.83), ($P = 0.013$) after adjusting for hypertension, total protamine dose and temperature after CPB. Compared with TA2, the relative risk of IR was 2.5 for TA1 (95% CI 1.02-6.12). The absolute risk difference was 11.3%. The number needed to treat with TA2 to reduce IR was 9 patients (95% CI: 5-107 patients).

In the omnibus test TA2 had significantly lower chest-tube bleeding ($P = 0.014$). Comparing both groups for chest bleeding at 24 hours, TA2 had lower bleeding than TA1 [978 (95% CI: 809-1147) vs 1198 (95%CI: 1017-1380) mL; $P = 0.010$, corrected-$P$ significant], which remained significant after adjusting for surgery-related bleeding ($P = 0.014$, corrected-$P$ significant). On summing intraoperative and 24 h postoperative bleeding, the effect of TA2 was significant: [1341 (95% CI: 1197-1486) vs 1538 (95%CI: 1391-1686) mL; $P = 0.016$, corrected-$P$ significant]. Also in the omnibus test, TA2 had significantly lower D-dimer ($P = 0.038$) than TA1 (Figure 3). TA2 had lower D-dimer levels at 24 hours [489 (95% CI: 437-540) vs. 621 (95% CI: 563-679) ng/mL; $P = 0.01$, corrected-$P$ significant].

TA2 showed significant reduction of maximum CPK values [407(95%CI: 259-671) vs 487(95%CI: 359-812)U/L; $P = 0.01$] and TnI [2.6(95%CI: 1.7-4.7) vs 3.6(95%CI: 2.7-6.3)U/L; $P > 0.01$]. TA2 required lower levels of norepinephrine at 24 h [0.06 (95%CI: 0.03-0.09) vs 0.20 (95%CI:0.05-0.35), $P = 0.03$, adjusted for dobutamine [F(1.40) = 6.6; $P = 0.014$, corrected-$P$ significant].

No differences were found in hemoderivative requirements or other parameters (Table 2).

We found a direct relationship between IL-6 at ICU arrival and: temperature (rho = 0.26; $P < 0.01$), D-dimer (rho = 0.24; $P < 0.01$), norepinephrine (rho = 0.33; $P < 0.01$), TnI (rho = 0.37; $P < 0.01$), CK(rho = 0.37; $P < 0.01$), CK-MB(rho = 0.33; $P < 0.01$) and lactic acid (rho = 0.46; $P < 0.01$) at arrival. Similarly, a direct correlation was observed between IL-6 at 4 h with temperature (rho = 0.23; $P < 0.01$), norepinephrine (rho = 0.25; $P < 0.01$), TnI (rho = 0.42; $P < 0.01$) and lactic acid (rho = 0.19; $P = 0.03$) at 4 h and chest tube bleeding at 24 h (rho = 0.18; $P = 0.03$) and at chest-tube withdrawal (rho = 0.20; $P = 0.02$), and an inverse relationship with systolic blood pressure at 4 h (rho = -0.17; $P = 0.05$).

Seizure was present in 2 (1.3%) and stroke in 3 (1.9%) patients. Acute kidney injury occurred in 14 (8.8%) patients, and 7(4.4%) needed dialysis. Finally, 3 (1.9%) suffered myocardial infarction. Seven patients required re-operation for bleeding: 5 in TA1 and 2 in TA2, ($P = 0.44$). There were 9 deaths, without significant differences between groups: 3 (3.8%) in TA1 versus 6 (7.6%) in TA2 ($P = 0.29$). Statistically, there were no significant differences in expected vs. observed mortality between the two groups. According to logistic Euroscore, the rates of mortality were: TA1-observed = 3.8% (3/80) and TA1-expected = 3.25% (3/80), ($P = 0.99$) and TA2-observed = 7.6% (6/80) and TA2-expected = 3.27% (3/80), ($P = 0.11$). There were no significant differences between
groups in cerebrovascular events, renal pathology, myocardial infarction, mechanical ventilation or ICU stay after surgery, nor when comparing composite adverse effects (Table 2).

**Discussion**

The clinical definition of IR based primarily on early hyperthermia with a hyperdynamic state is accompanied by higher levels of IL-6 at 4 h than in other patients. Peak levels of this interleukin is observed in these first hours of the postoperative period, as found by our team in a previous study [6] and by others [16,17]. The presence of hyperthermia in the criteria used avoids the potential confounding effect of vasoactive drugs on the associated hyperdynamic state.

Our findings indicate that prolonged inhibition of fibrinolysis by a postoperative dose of TA reduces IR and bleeding in CPB patients. TA1 patients presented higher levels of D-dimer, greater bleeding and IR than TA2 patients who received a second dose after CPB.

Several mechanisms have been proposed to explain IR after CPB, including contact activation, ischemia-reperfusion, and endotoxemia. These triggers may activate numerous systems involving complement, cytokines, immune cellular response and coagulation-fibrinolytic cascades [4]. These systems are closely interconnected and provide continuous feedback, so the release of cytokines [18] or activation of the complement system [19] may amplify the fibrinolytic response. This in turn may re-activate the release of inflammatory mediators by plasmin and
D-dimer [3,20,21]. This amplified IR is especially relevant in CPB.

In a previous study, we observed significantly higher levels of IL-6 in patients with IR and TA was effective in reducing this response [6]. Thus in the present study we focused on IL-6 and fibrinolysis. In addition to the feedback between the release of inflammatory markers and fibrinolysis, other components must be considered in the release of these markers. After CPB (Figure 2) we observed a clear increase in the levels of IL-6 and other interleukins, which interact with each other [16,17] and are involved in producing fever (“postperfusion syndrome”) [22]. Also, oxidative stress induced by norepinephrine may release IL-6 in other settings [23]. In this study, we observed no differences in IL-6 levels between groups, probably because both them received antifibrinolytic.

Proinflammatory cytokines may contribute to inflammatory response, myocardial ischemia-reperfusion injury and hemodynamic instability after clinical CPB. This myocardial dysfunction has been highlighted in diverse studies through the association between cytokine levels (IL-6) and markers of myocardial tissue damage such as TnI y CK [24,25].

In the present study, patients developing IR showed higher levels of IL-6 than those who did not, together with worse hemodynamic status. The association between greater cytokine (IL-6) release, activation of fibrinolysis (D-dimer), higher temperature, higher levels

| Table 1 Baseline characteristics of treatment groups |
|-----------------------------------------------|
|                      | Tranexamic acid |                      |                      |
|                      | TA1 group       | TA2 group            | P                  |
|                      | (40-0 mg/Kg)   | (40-40 mg/Kg)       |                    |
| (n = 80)            |                 | (n = 80)             |                    |
| Demographics        |                 |                      |                    |
| Age (years)         | 65 (62-69)      | 68 (65-70)           | 0.24               |
| Male sex, n (%)     | 54 (67.5)       | 49 (61.3)            | 0.41               |
| Parsonnet           | 9.2 (7.2-11.2)  | 10.5 (8.4-12.5)      | 0.30               |
| Euroscore           | 4 (3-6)         | 4 (3-7)              | 0.38               |
| Logistic Euroscorea| 3.25(1.83-5.53) | 3.27(1.75-6.68)      | 0.84               |
| Body mass index (Kg/m²) | 282 (274.29)  | 277 (266.28-8)       | 0.50               |
| Comorbidity         |                 |                      |                    |
| Hypertension, n (%) | 43 (53.8)       | 53 (66.3)            | 0.11               |
| Diabetes, n (%)     | 36 (45)         | 28 (35)              | 0.42               |
| Medical treatment   |                 |                      |                    |
| Angiotensin-converting enzyme inhibitors, n (%) | 28 (35)        | 22 (27.5)            | 0.31               |
| Preoperative parameters |             |                      |                    |
| Platelet count (× 10³ ml⁻¹) | 247 (227-267) | 262 (239-285)       | 0.48               |
| D-dimer (ng/ml)     | 347 (217-476)  | 287 (221-353)        | 0.95               |
| International normalized ratio | 1.04 (1.01-1.07) | 1.05 (1.01-1.09) | 0.28               |
| Cardiac intervention|                 |                      |                    |
| Coronary, n (%)     | 45 (56.3)       | 39 (48.8)            | 0.51               |
| Valvular, n (%)     | 25 (31.3)       | 31 (38.8)            | 0.42               |
| Both, n (%)         | 9 (11.3)        | 7 (8.8)              | 0.51               |
| Other, n (%)b       | 1 (1.3)         | 3 (3.8)              | 0.51               |
| Second intervention, n (%) | 4 (5)          | 3 (3.8)              | 0.51               |
| Surgical data       |                 |                      |                    |
| Temperature during cardiopulmonary bypass (°C) | 32.3 (32.32.5) | 32.3 (32.1-32.5) | 0.78               |
| Aortic clamp time (min) | 53 (49-58)     | 51 (46-57)           | 0.61               |
| Cardiopulmonary bypass time(min) | 88 (82-94)   | 84 (77-92)           | 0.45               |
| Temperature after cardiopulmonary bypass (°C) | 35.5 (35.3-35.6) | 35.7 (35.5-35.8) | 0.03               |
| Total heparin dose (IU/Kg) | 391 (371-412) | 400 (379-421)       | 0.56               |
| Total protamine dose (mg/Kg) | 2.7 (2.6-2.8) | 2.9 (2.8-3.1)       | 0.04               |
| Heparine/protamine  | 1.45 (1.37-1.53) | 1.39 (1.33-1.44) | 0.29               |
| Blood salvage (ml)  | 724 (663-784)  | 703 (636-767)        | 0.64               |

Values expressed as mean and 95% confidence interval; frequencies and percentages; median and percentiles.

bInter-atrial communication.
of TnI, CK, CK-MB, and increased hemodynamic instability (norepinephrine requirements and higher lactate levels) in the immediate postoperative period support the inter-relation between inflammation and fibrinolysis [18-20].

The protective effect of TA regarding IR, more evident in the TA2 group, was also reflected in less postoperative myocardial tissue damage.

Optimal use of inotropes or vasopressors in the periparative period of cardiac surgery remains controversial.

**Figure 2** Mixed ANOVA showing the relationship between IR and IL-6 during the follow up

**Figure 3** Mixed ANOVA showing the relationship between Tranexamic acid doses and D-Dimer during the follow up
We usually employ a combination of dobutamine plus norepinephrine in patients who develop postoperative cardiac dysfunction when there is associated hypotension, to maintain an adequate perfusion pressure. This would justify the use of norepinephrine in patients who do not develop IR [26,27]. Although the initial analysis revealed no differences in the need for norepinephrine in the first 24 hours postoperatively between the treatment groups, differences did appear at 24 h after adjusting for the dose of dobutamine at the time.

Although TA effectively reduces bleeding after cardiac surgery, doses vary widely [12,13]. Most are based on an

| Table 2 Outcomes of treatment groups |
|-------------------------------------|
| TA1 group | TA2 group | P |
| (40-0 mg/Kg) | (40-40 mg/Kg) | |
| (n = 80) | (n = 80) | |
| D-dimer (ng/mL) 0-h | 363 (307-420) | 311 (257-365) | 0.038* |
| D-dimer (ng/mL) 4-h | 416 (376-455) | 283 (254-312) | |
| D-dimer (ng/mL) 24 h | 621 (563-679) | 489 (437-540) | |
| Chest tube bleeding (cc) 0 h | 136 (109-163) | 109 (89-129) | 0.014† |
| Chest tube bleeding (cc) 4 h | 366 (282-449) | 263 (222-304) | |
| Chest tube bleeding (cc) 24 h | 826 (704-949) | 671 (549-793) | |
| Chest tube total bleeding (cc) | 1198 (1017-1380) | 978 (809-1147) | |
| Transfused patients at 24 h (%) | 22 (27.8) | 19 (23.8) | 0.55 |
| Inflammatory response (%) | 15 (18.8) | 6 (7.5) | 0.03 |
| Temperature > 38 °C n(%) | 15(18.8) | 6(7.5) | 0.03 |
| Cardiac index > 3.5 (L/min/m²) n(%) | 65(82.3) | 58(75.3) | 0.29 |
| Systemic vascular resistance index <1600 (dyne · sec/cm² per m²) n(%) | 31(39.2) | 21(27.6) | 0.13 |
| Interleukine-6 (pg/mL) 0-h | 281 (139-423) | 239 (177-302) | 0.79‡ |
| Interleukine-6 (pg/mL) 4-h | 511 (341-679) | 470 (327-613) | |
| Creatine kinase (U/L) 0 h | 257 (207-352) | 208 (160-315) | 0.12¶ |
| Creatine kinase (U/L) 4 h | 336 (253-460) | 281 (228-414) | |
| Creatine kinase (U/L) 24 h | 447 (336-807) | 399 (266-657) | |
| Creatine kinase peak (U/L) | 487 (359-812) | 407 (259-671) | 0.01 |
| Troponin I (ng/mL) 0 h | 1.3 (1-2.8) | 1.2 (0.6-1.7) | 0.88** |
| Troponin I (ng/mL) 4 h | 3.4 (2.4-5.3) | 2.3 (1.6-3.9) | |
| Troponin I (ng/mL) 24 h | 1.8 (1.2-3.3) | 1.6 (1.1-3.3) | |
| Troponin I peak (ng/mL) | 3.6 (2.7-6.5) | 2.6 (1.7-4.7) | <0.01 |
| Norepinephrine (mcg/Kg/min) 0 h | 0.07(0.03-0.12) | 0.06(0.02-0.10) | 0.46†† |
| Norepinephrine (mcg/Kg/min) 4 h | 0.12(0.04-0.19) | 0.09(0.03-0.14) | |
| Norepinephrine (mcg/Kg/min) 24 h | 0.20(0.05-0.35) | 0.06(0.03-0.09) | |
| Dobutamine (mcg/Kg/min) 0 h | 1.77(1.03-2.51) | 1.68(0.99-2.38) | 0.96‡‡ |
| Dobutamine (mcg/Kg/min) 4 h | 1.60(0.80-2.41) | 1.69(0.94-2.44) | |
| Dobutamine (mcg/Kg/min) 24 h | 1.19(0.47-1.92) | 1.28(0.59-1.98) | |
| Mechanical ventilation (h)† | 7 (5-13) | 7 (6-15) | 0.60 |
| Re-intervention, n (%) | 5 (6.3) | 2 (2.5) | 0.44 |
| Postoperative stroke, n (%) | 1 (1.3) | 2 (2.5) | 0.56 |
| Seizures, n (%) | 0 (0) | 2 (2.5) | 0.49 |
| Renal dysfunction, n (%) | 6 (7.5) | 7 (8.9) | 0.75 |
| Renal failure, n (%) | 4 (5) | 3 (3.8) | 0.70 |
| Myocardial infarction, n (%) | 2 (2.5) | 1 (1.3) | 0.56 |
| Intensive care length of stay (days)§ | 3 (2-5) | 3 (2-5) | 0.26 |
| Mortality, n (%) | 3 (3.8) | 6 (7.6) | 0.29 |
| Composite Adverse Effects(%) | 14(17.5) | 11(13.8) | 0.51 |

Values expressed as means and 95% confidence interval; frequencies and percentages.

*D-dimer levels at 24 hours (P = 0.01, corrected P significant).  † Chest bleeding at 24 hours (P = 0.01, corrected P significant).  †† Norepinephrine at 24 h adjusted for dobutamine at 24 h (P = 0.014, corrected P significant).  ‡‡ Values expressed as median and interquartile range

* † †‡ ¶ ** †† ‡‡ P values correspond to omnibus F-scores and were obtained using Mixed ANOVA

Jiménez et al. Journal of Cardiothoracic Surgery 2011, 6:138
http://www.cardiothoracicsurgery.org/content/6/1/138
Page 8 of 10
initial dose and subsequent infusion, which can result in high cumulative doses. TA half-life is 80 min, and the effect of a single dose (TA1) is nearly 100% inhibition of plasmin activity [14] in the immediate postoperative period, so a second dose administered at the end of surgery may prevent IR and bleeding complications, since enhanced fibrinolysis might be expected after heparin reversal [28].

Thus the dosing schedule used in our study ensures complete inhibition of fibrinolysis, although no pharmacokinetic information was available. With the second dose we wished to investigate the possible benefit of postoperative inhibition of fibrinolysis on IR.

It is questionable whether the statistically smaller blood loss in TA2 group is really clinically relevant, in terms of transfusion requirements. The use of hemoderivatives partly depends on the transfusion policy of each center, as in our case. However, given that numerous authors concur on the need for antifibrinolytic agents in cardiac surgery [29], we believe the protective effect of the TA2 dosing schedule used in the present study on IR and clinical parameters should be considered.

The incidence of non-ischemic clinical seizure varies from 2.7% to 4.6% in most major surgical procedures [8-10], only 0.4% in CABG [9], but as high as 6.7% [8] or 7.9% [9] in open chamber surgery. This adverse effect has been reported with different several dosing schedules and cumulative doses of 61-259 mg/kg [8-10].

The incidence of non-ischemic clinical seizure was 0% in the single-dose group versus 2.5% in the double-dose group (non-significant difference); one patient underwent CABG and the other open chamber surgery (valve replacement), and both had associated renal dysfunction. Although our incidence was below the limits reported by other authors, with slightly higher cumulative doses than those used by Martin K et al [9] and lower than Sander M et al [8] and Murkin JM et al [10], there seems to be a certain dose-dependent relationship with seizure.

Tranexamic acid has been shown to have an epileptogenic effect in animals [30]. The suspected mechanism is a γ-amino butyric acid-driven inhibition of the central nervous system [31]. The patho-mechanism of the two seizures recorded in our study remains undetermined. Both occurred in patients with postoperative renal dysfunction which facilitates accumulation of the drug, and one patient underwent aortic valve surgery where micro-plaque dislodgement or the presence of micobubbles, which inevitably remain after closing the heart, could have triggered the seizure. This may also partly explain the higher incidence of seizure in open chamber surgery.

Cerebrovascular events, renal pathology and myocardial infarction were similar to those reported previously [32]. Hospitalization and mortality were similar in both groups.

Limitations
With 80 patients in each group, we empirically estimated a 13% difference between the incidence rates of IR, because in the balance between safety and effectiveness, we preferred safety. Although the empirical power for the observed proportions (18.8 vs. 7.5) was 67%, the study was sufficiently powered and significant differences were found at the end of the study.

Although the incidence of adverse events observed are consistent with that reported in other series, the study was underpowered to be able to affirm that the dosing schedule was safe since the sample size was calculated for IR.

Only IL-6 was measured as a biochemical marker of inflammatory response to CPB. However, this cytokine is widely used in this context, as shown in the literature [16,17].

Blood levels of TA were not measured, but the pharmacokinetic profile of this drug has been previously studied by other authors and the dosing schedule was based on their findings [14].

Lastly, the experimental nature of this single-center study with CPB patients undergoing a particular surgical technique (with non-coated circuits), limits the external validity of our findings.

Conclusions
In conclusion, an additional postoperative dose of TA may reduce IR and postoperative bleeding (but not transfusion requirements) in CPB patients. A question which remains unanswered is whether the dose used was ideal in terms of safety, but in terms of effectiveness we have no doubt.

List of abbreviations
CPB: Cardiopulmonary bypass; TA: Tranexamic acid; IR: Inflammatory response; MOF: Multiorganic organ failure; ICU: Intensive care unit; PT: Prothrombin time; IL-6: Interleukin-6.

Acknowledgements
The authors wish to thank the following people: all the Nursing personnel of the Intensive Care Unit, Hospital Universitario de Canarias for their collaboration, and Michael McLean for help with the English version of the manuscript.

Author details
1Critical Care Department. Hospital Universitario de Canarias. Ofra s/n, La Cuesta. 38320-La Laguna. España.
2Nephrology Department. Hospital Universitario Carlos Haya, 29010-Málaga. España.
3Mixed Research Unit. Hospital Universitario de Canarias. Ofra s/n, La Cuesta. 38320-La Laguna. España.
4Hematology Laboratory. Hospital Universitario de Canarias. Ofra s/n, La Cuesta. 38320-La Laguna. España.
5Biochemical laboratory. Hospital Universitario de Canarias. Ofra s/n, La Cuesta. 38320-La Laguna. España.
6Cardiac Surgery Department. Hospital Universitario de Canarias. Ofra s/n, La Cuesta. 38320-La Laguna. Tenerife. España.
Authors’ contributions
JJI and JLI were responsible for the study design, data collection, processing blood samples during the study, statistical analysis, data interpretation, and drafting the manuscript. DH, AJ were responsible for the statistical analysis, data interpretation, and drafting the manuscript. MB, LL, RP, and MLM were responsible for data collection and processing blood simples during the study and provided useful suggestions. PM and JMR were responsible for determination of coagulation-fibrinolytic parameters and interpretation. JMB and BM, was responsible for determination of IL-6 and interpretation. RM was the surgical team and was responsible for preoperative clinical and analytical data collection. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 6 July 2011 Accepted: 14 October 2011
Published: 14 October 2011

References
1. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O’Connor GT, Dacey LJ: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999, 99:81-89.
2. Dunn CJ, Gao KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57:1005-1023.
3. Greilich PE, Bourge CF, Whitten CW, Chi L, Dimasi JM, Jessen ME: Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003, 126:1498-1503.
4. Jimenez JJ, Illarriene JL, Lorenzo L, Rodriguez JM, Hernandez D: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Critical Care 2007, 11:R117.
5. Koster A, Schimer U: Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011, 24:92-97.
6. Sander M, Spies CD, Martiny V, Rosenthal Ch, Wernecke KD, Heymann Ch: Re-evaluation of the role of antifibrinolytic therapy during cardiopulmonary bypass with aprotinin. Arterioscler Thromb Vasc Biol 2003, 23:1191-1194.

7. Karski JM, Illarrien JL, Lorente L, Rodriguez JM, Hernandez D: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Critical Care 2007, 11:R117.
8. Koster A, Schimer U: Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011, 24:92-97.
9. Sander M, Spies CD, Martiny V, Rosenthal Ch, Wermke KD, Heymann Ch: Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010, 14:R148.
10. Martin K, Weissner G, Breuer T, Lange R, Tarsass P: The risk of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008, 107:1783-1790.
11. Morin JM, Faller F, Granton J, Young B, Burt C, Chu M: High-Dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010, 110:350-353.
12. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001, 357:1191-1194.
13. Karski JM, Dowd NP, Joiner R, Carroll J, Peniston C, Bailey K, Glynn MF, Teasdale SJ, Cheng DC: The effect of three different doses of Tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C). J Thorac Cardiovasc Anesth 1998, 12:642-646.
14. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmit JL: The dose-response relationship of Tranexamic acid. Anesthesiology 1995, 82:383-392.
15. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J: Pharmacokinetics of Tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002, 97:390-399.
16. Bellomo R, Kellum JA, Ronco C: Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Medicine 2007, 33:409-413.
17. Meng QH, Zhu S, Sohn N, Mycky T, Shaw SA, Dalshaug G, Krahm J: Release of cardiac biochemical and inflammatory markers in patients on cardiopulmonary bypass undergoing coronary artery bypass grafting. J Card Surg 2008, 23:681-687.
18. Roth-issigkeit A, Hasselbach L, Ocklitz E, Birkner S, Rott U, Gerhing H, Schmucker P, Rink L, Seyfarth M: Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol 2001, 125:80-88.
19. Jansen PM, Boermeester MA, Fischer E, de Jong W, van der Poll T, Moldaver LL, Hack CE, Lowry SF: Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretary-type phospholipase A2 in sepsis: studies in nonhuman primates alter interleukin-1 alpha administration and during lethal bacteremia. Blood 1995, 86:1027-1034.
20. Reintartz J, Hansch GM, Kramer MD: Complement component C7 is a plasminogen-binding protein. J Immunol 1995, 154:844-850.
21. Syrosvets T, Jendrach M, Rohwedder A, Schulle A, Simmer T: Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NFkappaB activation. Blood 2001, 97:3941-3950.
22. Liu Q, Laumonnier Y, Syrosvets T, Simmer T: Plasmin Triggers Cytokine Induction in Human Monocyte-Derived Macrophages. Arterioscler Thromb Vasc Biol 2007, 27:1383-1389.
23. Bouter H, Schippers EF, Lelma SA, Versteegh MI, Ros P, Guiot HF, Frolich M, van Dissel JT: No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: a randomized, placebo-controlled study. Crit Care Med 2002, 30:38-43.
24. Neri M, Cerretani D, Fiaschi AL, Laghi PF, Lazzerini PE, Maione AB, Michel L, Bruni G, Cincotti G, Giorgi G, D’Erico S, Fiore C, Pomara C, Riezzo I, Turfiazzi E, Fineschi V: Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J Cell Mol Med 2007, 11:156-170.
25. Yuan S, LeClere J, Vincent JL: Cytokine Responses to Cardiopulmonary Bypass: Lessons Learned From Cardiac Transplantation. Ann Thorac Surg 1997, 63:269-276.
26. Hennein HA, Ebbia H, Rodriguez JL, Merritt SH, Bronstein MH, Leung JM, Mangano DT, Greenfield LJ, Rankin JS: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994, 108:626-635.
27. Mebazaa A, Pittis AA, Rudiger A, Toller W, Longrois D, Schmid ER, Leung JM, Mangano DT, Greenfield LJ, Rankin JS: Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock: A prospective, randomized pilot study. Crit Care Med 2011, 39:450-453.
28. Kuypel F, Dansis G, Mueller-Chrusitz A, Kulka PM, Zenz M, Weibelbach A: Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. Blood Coag Fibrinolysis 2003, 14:147-153.
29. Beattie WS, Karkouti K: The post-BART anti-fibrinolytic dilemma? J Cardiothorac Vasc Anesth 2011, 25:3-5.
30. Yamaura A, Nakamura T, Makino H, Hagihara Y: Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature. Eur Neurol 1980, 19:77-84.
31. Frittmuller R, Schlaug MG, Berger M, Hopf R, Huk S, Sieghart W, Redl H: Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutric acid(A) receptorantagonistic effect. J Pharmacol Exp Ther 2002, 301:168-73.
32. Oakes DA, Mangano CT: Cardiopulmonary bypass in 2009: Achieving and circulating best practices. Anesth Analg 2009, 108:1368-1370.